Royce & Associates LP decreased its holdings in Entellus Medical, Inc. (NASDAQ:ENTL) by 19.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,526 shares of the medical technology company’s stock after selling 32,474 shares during the quarter. Royce & Associates LP owned about 0.61% of Entellus Medical worth $2,228,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also made changes to their positions in ENTL. Bank of America Corp DE lifted its stake in Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after acquiring an additional 2,594 shares during the period. First Mercantile Trust Co. lifted its stake in Entellus Medical by 45.3% in the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after acquiring an additional 2,557 shares during the period. Parametric Portfolio Associates LLC lifted its stake in Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after acquiring an additional 573 shares during the period. Rhumbline Advisers purchased a new stake in Entellus Medical in the second quarter worth $199,000. Finally, Swiss National Bank lifted its stake in Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock worth $244,000 after acquiring an additional 8,800 shares during the period. 70.41% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Entellus Medical, Inc. (ENTL) Shares Sold by Royce & Associates LP” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/09/13/entellus-medical-inc-entl-shares-sold-by-royce-associates-lp.html.
ENTL has been the subject of a number of research analyst reports. BidaskClub lowered Entellus Medical from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Entellus Medical in a research note on Wednesday, July 12th. Canaccord Genuity set a $18.00 price target on Entellus Medical and gave the stock a “hold” rating in a research note on Monday, May 22nd. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, ValuEngine raised Entellus Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $21.71.
Entellus Medical, Inc. (NASDAQ:ENTL) opened at 17.13 on Wednesday. Entellus Medical, Inc. has a 12 month low of $12.31 and a 12 month high of $22.57. The firm’s 50-day moving average price is $17.36 and its 200 day moving average price is $14.33. The stock’s market cap is $434.61 million.
Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). The firm had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. Entellus Medical’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.27) earnings per share. On average, analysts anticipate that Entellus Medical, Inc. will post ($1.61) earnings per share for the current year.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical, Inc. (NASDAQ:ENTL).
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.